featured
Testosterone Suppression Plus Either Enzalutamide or Standard Anti-Androgen Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Lancet Oncol 2023 Apr 01;24(4)323-334, CJ Sweeney, AJ Martin, MR Stockler, S Begbie, L Cheung, KN Chi, S Chowdhury, M Frydenberg, LG Horvath, AM Joshua, NJ Lawrence, G Marx, J McCaffrey, R McDermott, M McJannett, SA North, F Parnis, W Parulekar, DW Pook, MN Reaume, SK Sandhu, A Tan, TH Tan, A Thomson, F Vera-Badillo, SG Williams, D Winter, S Yip, AY Zhang, RR Zielinski, ID DavisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.